Skip to main content
SpringerLink
Log in

Gefitinib not noninferior to docetaxel for NSCLC

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. AstraZeneca.IRESSA (Rm) (gefitinib) 250 mg tablets: failure to demonstrate non-inferiority in overall survival versus docetaxel. Results from a Japanese Phase II Study in 2nd-line non-small cell lung cancer (NSCLC) patients. Internet Document: [2 pages], 4 Sep 2007. Available from: URL: http://www.hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gefitinib not noninferior to docetaxel for NSCLC. React. Wkly. 1174, 2 (2007). https://doi.org/10.2165/00128415-200711740-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711740-00003

Keywords

Search

Navigation